CorMatrix Cardiovascular has completed a trial of its CorMatrix ECM technology and confirmed safety of its usage to close the pericardium of patients undergoing postoperative coronary artery bypass grafting (CABG).

Preliminary results show that the study’s safety endpoints concerning the use of the device close to the pericardium were met.

However, the primary endpoint of new onset postoperative atrial fibrillation was not met, with no statistically significant difference between treatment and control groups.

As part of the New Onset Post-Operative Atrial Fibrillation Clinical Trial, the new technology was trialled on patients undergoing first-time CABG at 15 US clinical sites.

“Preliminary results show that the study’s safety endpoints concerning the use of the device close to the pericardium were met.”

CorMatrix chairman and CEO David Camp said; “We will continue to evaluate the clinical trial data to better understand the factors that may affect postoperative atrial fibrillation.”

The trial also eliminated concerns that closing the pericardium may cause coronary bypass grafts to ‘kink’ and close postoperatively, and also showed no drastic change in the incidence of graft occlusion when using CorMatrix ECM technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CorMatrix ECM, which is a naturally-occurring extracellular matrix biomaterial, supports native tissue repair by allowing a patient’s own cells to repopulate and fix damaged tissues.

Deployed at over 720 hospitals across the US, the CorMatrix ECM has been implanted in patients during 70,000 cardiac processes.